Biotechnology Ultragenyx (Nasdaq: RARE), a biopharmaceutical company focused on developing novel therapies for ultra-rare diseases, announced on Tuesday that the European Commission had granted marketing authorization for Mepsevii (vestronidase alfa), a therapy for non-neurological manifestations of mucopolysaccharidosis VII (Sly syndrome). 28 August 2018